Cisplatin-based chemotherapy does not eliminate the risk of a second testicular cancer

Br J Urol. 1989 May;63(5):531-4. doi: 10.1111/j.1464-410x.1989.tb05951.x.

Abstract

Of 781 patients with germ cell cancer, 14 developed a second (subsequent) testicular cancer during follow-up. The incidence was not related to the treatment of the first germ cell cancer. In particular, adequate cisplatin-based chemotherapy did not reduce the risk of developing a second tumour. Screening programmes in patients with previous germ cell tumours should include all patients, irrespective of prior treatment.

MeSH terms

  • Adult
  • Cisplatin / therapeutic use*
  • Combined Modality Therapy
  • Humans
  • Male
  • Neoplasm Recurrence, Local
  • Neoplasms, Germ Cell and Embryonal / drug therapy*
  • Neoplasms, Germ Cell and Embryonal / radiotherapy
  • Risk Factors
  • Testicular Neoplasms / drug therapy*
  • Testicular Neoplasms / radiotherapy

Substances

  • Cisplatin